| A. 6 INDIGO: a global, randomized, double-blinded, Phase 3 study of vorasidenib versus placebo in patients with grade 2 glioma with an IDH1/2 mutation (mIDH1/2) JR Perry, IK Mellinghoff, M van den Bent, DT Blumenthal, M Touat, ... Canadian Journal of Neurological Sciences 51 (s1), S4-S4, 2024 | | 2024 |
| Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study AB Ercan, M Aronson, NR Fernandez, Y Chang, A Levine, ZA Liu, L Negm, ... The Lancet Oncology 25 (5), 668-682, 2024 | 4 | 2024 |
| Suggested searches J Mok, JH Park, J Park, RA Chisholm, NP Kristensen, FE Rheindt, ... Perspective, 2024 | | 2024 |
| A Randomized, Double-blind, Phase 3 Study of Vorasidenib Versus Placebo in Patients with Mutant IDH1/2 Diffuse Glioma (INDIGO): Analysis of Health-related Quality of Life … K Peters, I Mellinghoff, M Van Den Bent, D Blumenthal, M Touat, J Clarke, ... Neurology 102 (17_supplement_1), 5113, 2024 | | 2024 |
| Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti–PD-1 Monotherapy: A Report from the International RRD Consortium A Das, NR Fernandez, A Levine, V Bianchi, LK Stengs, J Chung, L Negm, ... Cancer discovery 14 (2), 258-273, 2024 | 4 | 2024 |
| LTBK-06. IMPACT OF VORASIDENIB TREATMENT ON MUTANT IDH1 OR IDH2 DIFFUSE GLIOMA TUMOR GROWTH RATE: RESULTS FROM THE … P Wen, I Mellinghoff, M van den Bent, D Blumenthal, M Touat, K Peters, ... Neuro-Oncology 25 (Supplement_5), v310-v311, 2023 | 4 | 2023 |
| QOL-26. A RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY OF VORASIDENIB VS PLACEBO IN PATIENTS WITH MUTANT IDH1/2DIFFUSE GLIOMA (INDIGO … K Peters, I Mellinghoff, M van den Bent, D Blumenthal, M Touat, J Clarke, ... Neuro-Oncology 25 (Supplement_5), v254-v255, 2023 | 2 | 2023 |
| CTNI-51. A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF VORASIDENIB VS PLACEBO IN PATIENTS WITH MUTANT IDH1/2 DIFFUSE GLIOMA (INDIGO … T Cloughesy, I Mellinghoff, M van den Bent, D Blumenthal, M Touat, ... Neuro-Oncology 25 (Supplement_5), v86-v87, 2023 | 1 | 2023 |
| 498O INDIGO: A randomized, double-blinded, phase III study of vorasidenib versus placebo in IDH1 or IDH2 low-grade glioma D Blumenthal, IK Mellinghoff, MJ van den Bent, M Touat, K Peters, ... Annals of Oncology 34, S391, 2023 | | 2023 |
| INDIGO: A GLOBAL, RANDOMIZED, DOUBLE-BLINDED, PHASE 3 STUDY OF VORASIDENIB VERSUS PLACEBO IN PATIENTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1/2 MUTATION C McBain, IK Mellinghoff, MJ van den Bent, DT Blumenthal, M Touat, ... Neuro-Oncology 25 (Supplement_3), iii6-iii6, 2023 | | 2023 |
| Vorasidenib in IDH1-or IDH2-mutant low-grade glioma IK Mellinghoff, MJ Van Den Bent, DT Blumenthal, M Touat, KB Peters, ... New England Journal of Medicine 389 (7), 589-601, 2023 | 167 | 2023 |
| Collaborative privacy-preserving analysis of oncological data using multiparty homomorphic encryption R Geva, A Gusev, Y Polyakov, L Liram, O Rosolio, A Alexandru, N Genise, ... Proceedings of the National Academy of Sciences 120 (33), e2304415120, 2023 | 8 | 2023 |
| Immuno-PET imaging of CD69 visualizes T-cell activation and predicts survival following immunotherapy in murine glioblastoma M Nisnboym, SR Vincze, Z Xiong, CT Sneiderman, RA Raphael, B Li, ... Cancer Research Communications 3 (7), 1173-1188, 2023 | 3 | 2023 |
| INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation. IK Mellinghoff, MJ Van Den Bent, DT Blumenthal, M Touat, KB Peters, ... Journal of Clinical Oncology 41 (17_suppl), LBA1-LBA1, 2023 | 6 | 2023 |
| Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival following Immunotherapy in Murine GBM.(S17. 009) MN Ziv, SR Vincze, I Raphael, Z Xiong, CT Sneiderman, RA Raphael, B Li, ... Neurology 100 (17_supplement_2), 4969, 2023 | | 2023 |
| JOURNAL MEDICINE IK Mellinghoff, MJ van den Bent, DT Blumenthal, M Touat, KB Peters, ... | | 2023 |
| Practical lessons from treating medullary thyroid carcinoma patients harboring a RET-alteration: Pralsetinib-induced acute confusional state E Shachar, S Peleg Hasson, DT Blumenthal, M Fraenkel, Y Uri, I Wolf, ... Acta Oncologica 61 (7), 819-823, 2022 | | 2022 |
| A prospective, cohort study of SITOIGANAP to treat glioblastoma when given in combination with granulocyte-macrophage colony-stimulating factor/cyclophosphamide/bevacizumab … DA Bota, TH Taylor, N Lomeli, XT Kong, BD Fu, AH Schönthal, S Singer, ... Frontiers in Oncology 12, 934638, 2022 | 4 | 2022 |
| Imaging of malignant astrocytomas M Nisnboym, DT Blumenthal Handbook of Neuro-Oncology Neuroimaging, 503-520, 2022 | | 2022 |
| Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency A Das, S Sudhaman, D Morgenstern, A Coblentz, J Chung, SC Stone, ... Nature medicine 28 (1), 125-135, 2022 | 81 | 2022 |
